
Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(146 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(169 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(87 products)
- Src(79 products)
- Syk(37 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1430 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
BTK-IN-18
CAS:<p>BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.</p>Formula:C20H22Cl2N6OColor and Shape:SolidMolecular weight:433.33EGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Formula:C36H46BrN8O2PColor and Shape:SolidMolecular weight:733.68(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Formula:C22H20F2N6O2Purity:98%Color and Shape:SolidMolecular weight:438.43EVT801
CAS:<p>EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.</p>Formula:C19H21N5O3Purity:97.4%Color and Shape:SolidMolecular weight:367.4HDAC-IN-50
CAS:<p>HDAC-IN-50, a potent FGFR/HDAC inhibitor (IC50: 0.18-13 nM), induces apoptosis, cell cycle arrest, and shows anti-tumor activity.</p>Formula:C31H41N7O4Color and Shape:SolidMolecular weight:575.7MET kinase-IN-3
CAS:<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Formula:C25H16ClF2N5O2Color and Shape:SolidMolecular weight:491.88BTK-IN-19
CAS:<p>BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .</p>Formula:C21H22Cl2N6OColor and Shape:SolidMolecular weight:445.35BTK inhibitor 20
CAS:<p>BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .</p>Formula:C37H42N8O4Color and Shape:SolidMolecular weight:662.78CP-547632 TFA
CAS:<p>CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.</p>Formula:C22H25BrF5N5O5SPurity:98%Color and Shape:SolidMolecular weight:646.43HDAC/JAK/BRD4-IN-1
CAS:<p>HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.</p>Formula:C24H28N6O3Purity:98%Color and Shape:SolidMolecular weight:448.52Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Formula:C20H17N9Purity:98%Color and Shape:SolidMolecular weight:383.41EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97ALK/EGFR-IN-3
CAS:<p>ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-</p>Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Formula:C28H35ClFN7O3SColor and Shape:SolidMolecular weight:604.14Infigratinib-Boc
CAS:<p>Infigratinib-Boc, a derivative of the ATP-competitive pan-FGFR inhibitor Infigratinib, incorporates a Boc (t-Butyloxy carbonyl) group [1].</p>Formula:C29H35Cl2N7O5Color and Shape:SolidMolecular weight:632.54ALK/EGFR-IN-2
CAS:<p>ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.</p>Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12EGFR-IN-71
CAS:<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formula:C16H9ClIN3Color and Shape:SolidMolecular weight:405.62FLT3/ITD-IN-5
CAS:FLT3/ITD-IN-5 (Example 6) is an orally active inhibitor of both FLT3 and FLT3-ITD, exhibiting IC50 values of 0.088 nM and 0.348 nM, respectively. This compound is utilized in cancer research.Formula:C23H25N7O2Color and Shape:SolidMolecular weight:431.49HIF-2α-IN-1
CAS:<p>HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.</p>Formula:C16H8F5NO4SPurity:97.99%Color and Shape:SolidMolecular weight:405.3Brolucizumab
CAS:<p>Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.</p>Purity:95%Color and Shape:Liquid

